Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ATCell
- Development stage
- Unknown
- Lead developer
- American CryoStem
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
ATCell (also stylized as ATCELL™) is an autologous, adipose-derived mesenchymal stem cell (MSC) therapy developed by American CryoStem Corporation for the treatment of Post-Concussion Syndrome (PCS). The therapy involves the extraction of a patient's own adipose tissue, followed by the expansion of mesenchymal stem cells using the proprietary CryoStem Platform. These expanded cells are then delivered via intravenous infusion. ATCell is designed to address the complex central nervous system symptoms associated with PCS and Chronic Concussive Syndrome (CCS) by modulating the immune response and promoting tissue regeneration. In 2020, the FDA cleared an Investigational New Drug (IND) application for a Phase 1 clinical trial to evaluate the safety and efficacy of ATCell in retired military personnel and athletes who have sustained multiple concussions or mild traumatic brain injuries.
- Brand names
- ATCell
- Other names
- adipose derived stem cell infusionautologous adipose-derived mesenchymal stem cellsexpanded autologous adipose-derived mesenchymal stem cells
Beyond the preview
Go deeper on ATCell.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ATCell.